Ankit Mahadevia, CEO and President at Spero Therapeutics, Inc. (SPRO), sold 774 shares at $14.25 ($11K) on 2020-09-08, disclosed to the SEC on 2020-09-10.
Scheduled sale ($11k) by CEO and President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| SPRO | SELL | 2024-08-29 | $8K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |